GENI
NEUTRALGENinCode Plc Announces Holding(s) in Company
The healthcare diagnostics company has announced changes to its major shareholders.
GENinCode
2.9250GBX
2.63%
Market Cap
8.39M
Volume
294.48k
21% of avg
P/E Ratio
-1.46
EPS (TTM)
-2
Beta
0.86
Day Range
2.7550p - 2.9900p
52 Week Range
1.0000p2.9250p8.5000p
2.9250p
Upcoming Events
Q1 2026
GENinCode to submit additional data to FDA for De Novo assessment
High Impact Event
GENI
VERY GOODGENinCode partners with Thermo Fisher to scale CARDIO inCode-Score® test globally
The diagnostics company has partnered with Thermo Fisher Scientific to scale the commercialization of its CARDIO inCode-Score® genetic test for predicting and preventing heart disease across the US and Europe.
GENI
NEUTRALGENinCode's CARDIO inCode-Score® Test Approved in New York State
The healthcare diagnostics company has received approval from New York State for its CARDIO inCode-Score® genetic test, enabling wider commercial adoption in the US market.
GENI
NEUTRALGENinCode Publishes Landmark Cardiovascular Study in JACC: Advances
The predictive genetics company GENinCode has published a major clinical study in a leading cardiovascular journal, providing validation for its CARDIO inCode-Score® Polygenic Risk Score.
GENI
NEUTRALGENinCode Plc Announces Change in Shareholding
The healthcare diagnostics company has announced a change in shareholding, with Dowgate Group Limited reducing its stake in the business.
GENI
BADGENinCode Reports Revenue Growth but Lowers Full-Year Expectations Amid NHS Challenges and FDA Delays
The genetic testing firm reported revenue growth but faces headwinds from NHS restructuring and FDA approval delays, leading to lowered full-year expectations despite some positive developments in key markets.
GENI
NEUTRALGENinCode Plc Launches ROCA Test Surveillance Service for High-Risk Women
The healthcare company has launched a new surveillance service for women at high risk of ovarian cancer, working with NHS partners.
GENI
NEUTRALGENinCode Plc Announces Holding(s) in Company
The healthcare diagnostics company has announced changes to its major shareholders, with Maven Capital Partners UK LLP increasing its stake.
GENI
NEUTRALGENinCode Provides Update on Share Price Movement
The healthcare company provides a statement regarding recent share price movements, noting no specific reason for the changes.
GENI
NEUTRALGENinCode Plc Announces Notice of Results
The healthcare company announces the upcoming release of its interim results and plans for analyst and investor briefings.